CALCULATION OF PRESCRIBED DAILY DOSE OF ANTICOAGULANTS IN SOUTH INDIAN POPULATION
DOI:
https://doi.org/10.22159/ajpcr.2018.v11i6.23467Keywords:
Drug utilization evaluation, Anticoagulants, Prescribing daily dose, Defined daily doseAbstract
Objectives: The objectives of this study were to identify the commonly prescribed anticoagulants and to study the prescription pattern of anticoagulants in various indications and to calculate prescribing daily dose (PDD) and to compare PDD with defined daily dose of anticoagulants.
Methods: A total of 119 patients of all age groups, either of sex who are receiving anticoagulant therapy were included in this prospective observational study done in limited period of 6 months in the inpatient department of general medicine, gynecology, pediatrics, and surgery. Patients who are non-cooperative, cancer patients, psychiatric patients, and patients on hemodialysis and receiving anticoagulant treatment, and patients suffering from end-stage renal disease and hepatic failure are excluded from the study.
Results: In this study, we found that heparin, Low-molecular-weight heparins (LMWHs), warfarin, and acenocoumarol are the most commonly used drugs, of which heparin is highly prescribed. The use of anticoagulants in cardiovascular diseases was found to be high compared to other indications. PDD: DDD of warfarin is 0.46, acenocoumarol is 0.75, i.e., half the dose of drug showed its effectiveness, whereas heparin is 1.86, LMWH's is 2.9, i.e., double the dose is used to treat the disease effectively. A total of eight adverse drug reactions are observed with Vitamin K antagonists, i.e., 6.72%.
Conclusion: We observed that the anticoagulants were not prescribed as the WHO defined doses in the study site. Vitamin K antagonists were prescribed at half of the WHO defined doses and heparin derivatives were prescribed at increased doses and sometimes double the WHO defined doses; these variations may be due to disease characteristics or patient characteristics or drug characteristics.
Downloads
References
Parthasarthy G, Nyfort-Hansen K, Nahata M. Drug utilizayionevaluation. Sathvik B.S.A Textbook of Clinical Pharmacy Practice. Hyderabad: Universities Press; 2011. p. 447-59.
WHO. Introduction to Drug Utilization Research. Available from: https://www.whocc.no/filearchive/publications/drug_utilization_ research.pdf. [Last accessed on 2016 Sep 10].
Mukesh K, Vicky D, Shruti M, Dinesh S, Neha M, Lahkar M. Cardiovascular disease prevalence and drug utilization patterns at a tertiary care hospital in Northeastern India. Int J Pharm Pharm Sci 2016;8:116-9.
Colledge NR, Walker BR, Ralston SH. Anticoagulant and Antithrombotic Therapy, Principles and Practice of Davidson’s Medicine. 21st ed. India: Elsevier Publications; 2012. p. 1014.
Harvey RA. Anticoagulants, Lippincott’s Illustrated Reviews, Pharmacology. 5th ed. Philadelphia, PA: Wolters Liuwer Publications; 2011. p. 251-7.
Shazia A, Syed BS, Maqsood A. Drug utilization and economic impact of anticoagulants in unstable angina/non-ST elevation myocardial infarction in Karachi. Int J Pharm Pharm Sci 2015;7:183-5.
Galatro KM, Adams PC, Cohen M, McBride R, Blanke H. Bleeding complications and INR control of combined warfarin and low-dose aspirin therapy in patients with unstable angina and non-Q-wave myocardial infarction. J Thromb Thrombolysis 1998;5:249-55.
Di Biase L, Burkhardt JD, Santangeli P, Mohanty P, Sanchez JE, Horton R, et al. Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: Results from the role of coumadin in preventing thromboembolism in atrial fibrillation (AF) patients undergoing catheter ablation (COMPARE) randomized trial. Circulation 2014;129:2638-44.
Klein W, Buchwald A, Hillis SE, Monrad S, Sanz G, Turpie AG, et al. Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in unstable coronary artery disease study (FRIC) Circulation 1997;96:61-8.
Mosca L, Appel LJ, Benjamin EJ, Berra K, Chandra-Strobos N, Fabunmi RP, et al. Evidence-based guidelines for cardiovascular disease prevention in women. American heart association scientific statement. Arterioscler Thromb Vasc Biol 2004;24:e29-50.
Falck-Ytter Y, Francis CW, Johanson NA, Curley C, Dahl OE, Schulman S, et al. Prevention of VTE in orthopedic surgery patients: Antithrombotic therapy and prevention of thrombosis. 9th ed. American college of chest physicians evidence-based clinical practice guidelines. Chest 2012;141:e278S-325.
Published
How to Cite
Issue
Section
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.